View Future GrowthCipher Pharmaceuticals 過去の業績過去 基準チェック /66Cipher Pharmaceuticalsは、平均年間19.2%の収益成長を遂げていますが、 Pharmaceuticals業界の収益は、年間 成長しています。収益は、平均年間8.5% 20.9%収益成長率で 成長しています。 Cipher Pharmaceuticalsの自己資本利益率は23.3%であり、純利益率は60.6%です。主要情報19.21%収益成長率19.68%EPS成長率Pharmaceuticals 業界の成長7.33%収益成長率20.88%株主資本利益率23.25%ネット・マージン60.60%前回の決算情報31 Mar 2026最近の業績更新お知らせ • Apr 30Cipher Pharmaceuticals Inc. to Report Q1, 2026 Results on May 07, 2026Cipher Pharmaceuticals Inc. announced that they will report Q1, 2026 results After-Market on May 07, 2026お知らせ • Mar 05Cipher Pharmaceuticals Inc. to Report Q4, 2025 Results on Mar 12, 2026Cipher Pharmaceuticals Inc. announced that they will report Q4, 2025 results at 4:00 PM, US Eastern Standard Time on Mar 12, 2026お知らせ • Oct 30Cipher Pharmaceuticals Inc. to Report Q3, 2025 Results on Nov 06, 2025Cipher Pharmaceuticals Inc. announced that they will report Q3, 2025 results After-Market on Nov 06, 2025お知らせ • Jul 29Cipher Pharmaceuticals Inc. to Report Q2, 2025 Results on Aug 07, 2025Cipher Pharmaceuticals Inc. announced that they will report Q2, 2025 results at 4:00 PM, US Eastern Standard Time on Aug 07, 2025お知らせ • May 03Cipher Pharmaceuticals Inc. to Report Q1, 2025 Results on May 08, 2025Cipher Pharmaceuticals Inc. announced that they will report Q1, 2025 results After-Market on May 08, 2025お知らせ • Mar 12Cipher Pharmaceuticals Inc. to Report Q4, 2024 Results on Mar 18, 2025Cipher Pharmaceuticals Inc. announced that they will report Q4, 2024 results at 4:00 PM, US Eastern Standard Time on Mar 18, 2025すべての更新を表示Recent updatesBoard Change • Jul 01Insufficient new directorsNo new directors have joined the board in the last 3 years. The company's board is composed of: No new directors. 3 experienced directors. No highly experienced directors. Independent Director Doug Deeth was the last director to join the board, commencing their role in 2023. The company’s insufficient board refreshment is considered a risk according to the Simply Wall St Risk Model.お知らせ • Apr 30Cipher Pharmaceuticals Inc. to Report Q1, 2026 Results on May 07, 2026Cipher Pharmaceuticals Inc. announced that they will report Q1, 2026 results After-Market on May 07, 2026お知らせ • Apr 21Cipher Pharmaceuticals Inc., Annual General Meeting, Jun 18, 2026Cipher Pharmaceuticals Inc., Annual General Meeting, Jun 18, 2026. Location: ontario, toronto Canadaお知らせ • Mar 05Cipher Pharmaceuticals Inc. to Report Q4, 2025 Results on Mar 12, 2026Cipher Pharmaceuticals Inc. announced that they will report Q4, 2025 results at 4:00 PM, US Eastern Standard Time on Mar 12, 2026お知らせ • Jan 29Cipher Pharmaceuticals Announces Health Canada's Acceptance for Review of New Drug Submission for Natroba™? (Spinosad)Cipher Pharmaceuticals Inc. announced that Health Canada has accepted for review Cipher's new drug submission ("NDS") for Natroba™? (Spinosad), for the treatment of head lice and scabies. Natroba™? (Spinosad) is widely recognized as one of the most effective treatments for the two parasitic indications of head lice and sc babies in the U.S. It is superior to the widely used permethrin 1% for treating head lice and is the only treatment in the U.S. that meets the FDA's criteria for a " complete cure" (elimination of all signs and symptoms) in eradicating sc babies infestations with a single application. Cipher acquired Natroba™? (spinosad) in July 2024, and since acquisition has marketed and distributed the product in the United States ("U.S.) market, through its commercial infrastructure.お知らせ • Oct 30Cipher Pharmaceuticals Inc. to Report Q3, 2025 Results on Nov 06, 2025Cipher Pharmaceuticals Inc. announced that they will report Q3, 2025 results After-Market on Nov 06, 2025お知らせ • Aug 28Cipher Pharmaceuticals Inc. Announces the Passing of Board Director and Chairman of Audit Committee Harold M. WolkinCipher Pharmaceuticals Inc. announced the passing of Harold M. Wolkin, a valued member of the Company's Board of Directors and Chairman of the Audit Committee. Mr. Wolkin was a very active member of the Board and his deep understanding of the capital markets and unwavering commitment to the Company's growth and governance were tremendously valuable to the Company. During his tenure, he played a vital role in guiding strategic initiatives, supporting management, and representing the Company and its shareholders with integrity. Harold was a very well-known and highly respective member of the Canadian capital markets community and he will truly be missed by those that knew him.お知らせ • Jul 29Cipher Pharmaceuticals Inc. to Report Q2, 2025 Results on Aug 07, 2025Cipher Pharmaceuticals Inc. announced that they will report Q2, 2025 results at 4:00 PM, US Eastern Standard Time on Aug 07, 2025お知らせ • May 03Cipher Pharmaceuticals Inc. to Report Q1, 2025 Results on May 08, 2025Cipher Pharmaceuticals Inc. announced that they will report Q1, 2025 results After-Market on May 08, 2025お知らせ • Apr 09Cipher Pharmaceuticals Inc., Annual General Meeting, Jun 13, 2025Cipher Pharmaceuticals Inc., Annual General Meeting, Jun 13, 2025. Location: ontario, toronto Canadaお知らせ • Mar 12Cipher Pharmaceuticals Inc. to Report Q4, 2024 Results on Mar 18, 2025Cipher Pharmaceuticals Inc. announced that they will report Q4, 2024 results at 4:00 PM, US Eastern Standard Time on Mar 18, 2025Valuation Update With 7 Day Price Move • Nov 14Investor sentiment deteriorates as stock falls 17%After last week's 17% share price decline to €8.55, the stock trades at a forward P/E ratio of 12x. Average forward P/E is 14x in the Pharmaceuticals industry in Germany. Total returns to shareholders of 466% over the past three years.Reported Earnings • Nov 10Third quarter 2024 earnings released: EPS: US$0.011 (vs US$0.28 in 3Q 2023)Third quarter 2024 results: EPS: US$0.011 (down from US$0.28 in 3Q 2023). Revenue: US$10.4m (up 71% from 3Q 2023). Net income: US$283.0k (down 96% from 3Q 2023). Profit margin: 2.7% (down from 116% in 3Q 2023). Revenue is forecast to grow 19% p.a. on average during the next 3 years, compared to a 3.4% growth forecast for the Pharmaceuticals industry in Germany. Over the last 3 years on average, earnings per share has increased by 36% per year but the company’s share price has increased by 89% per year, which means it is tracking significantly ahead of earnings growth.New Risk • Nov 10New major risk - Earnings qualityThe company has a high level of non-cash earnings. Accrual ratio: 101% This is considered a major risk. Non-cash earnings can arise from many different things. However, if a company consistently has a high level of non-cash earnings, it may be a sign that they are recognizing revenue from customers before the full value of the sales are received as cash or they are not depreciating the value of their assets appropriately. These are practices that inflate earnings, while not providing a similar increase to cash flows. Companies in some select industries naturally have a high level of non-cash earnings and it is not a major concern. However, in the worst case scenario it can be an early sign of performance manipulation by management. Currently, the following risks have been identified for the company: Major Risk High level of non-cash earnings (101% accrual ratio). Minor Risks Share price has been volatile over the past 3 months (9.8% average weekly change). Profit margins are more than 30% lower than last year (60% net profit margin). Shareholders have been diluted in the past year (6.5% increase in shares outstanding).お知らせ • Nov 04Cipher Pharmaceuticals Inc. to Report Q3, 2024 Results on Nov 07, 2024Cipher Pharmaceuticals Inc. announced that they will report Q3, 2024 results After-Market on Nov 07, 2024お知らせ • Oct 08Cipher Pharmaceuticals Inc. Appoints Hamed Ghanei as Chief Business OfficerCipher Pharmaceuticals Inc. announced the appointment of Hamed Ghanei as Chief Business Officer. Dr. Ghanei has over 15 years of experience in specialty pharmaceuticals, venture funds, and healthcare investment banking. Throughout his career, he has led the evaluation of over 500 licensing and M&A opportunities and has been involved in five commercial product launches. He has successfully negotiated over 20 transactions with total value exceeding $1 billion. Dr. Ghanei holds a B.Sc. from the University of Waterloo, a M.Sc. in Microbiology and Biochemistry from the University of Guelph, and a Ph.D. in Medical Biophysics from the University of Toronto.Valuation Update With 7 Day Price Move • Oct 04Investor sentiment improves as stock rises 15%After last week's 15% share price gain to €10.20, the stock trades at a forward P/E ratio of 14x. Average forward P/E is 14x in the Pharmaceuticals industry in Germany. Total returns to shareholders of 534% over the past three years.Valuation Update With 7 Day Price Move • Sep 13Investor sentiment deteriorates as stock falls 21%After last week's 21% share price decline to €9.35, the stock trades at a forward P/E ratio of 14x. Average forward P/E is 15x in the Pharmaceuticals industry in Germany. Total returns to shareholders of 483% over the past three years.Valuation Update With 7 Day Price Move • Aug 20Investor sentiment improves as stock rises 18%After last week's 18% share price gain to €10.40, the stock trades at a forward P/E ratio of 14x. Average forward P/E is 17x in the Pharmaceuticals industry in Germany. Total returns to shareholders of 584% over the past three years.お知らせ • Aug 09+ 1 more updateCipher Pharmaceuticals Inc. Announces CFO ChangesEffective August 10, 2024, and as a result of the Natroba Acquisition, Cipher Pharmaceuticals Inc.'s Chief Financial Officer, Bryan Jacobs, will assume the title of President of the Company. His mandate will be to manage the transition and integration of the U.S. operations and commercial sales team. The Company's Vice President, Finance, Ryan Mailling, has in turn been appointed as the Chief Financial Officer of the Company, taking over from Mr. Jacobs.Reported Earnings • Aug 09Second quarter 2024 earnings released: EPS: US$0.12 (vs US$0.12 in 2Q 2023)Second quarter 2024 results: EPS: US$0.12 (down from US$0.12 in 2Q 2023). Revenue: US$5.30m (flat on 2Q 2023). Net income: US$3.00m (down 2.5% from 2Q 2023). Profit margin: 56% (down from 58% in 2Q 2023). Revenue is forecast to grow 20% p.a. on average during the next 3 years, compared to a 3.8% growth forecast for the Pharmaceuticals industry in Germany. Over the last 3 years on average, earnings per share has increased by 49% per year but the company’s share price has increased by 102% per year, which means it is tracking significantly ahead of earnings growth.お知らせ • Aug 02Cipher Pharmaceuticals Inc. to Report Q2, 2024 Results on Aug 08, 2024Cipher Pharmaceuticals Inc. announced that they will report Q2, 2024 results After-Market on Aug 08, 2024New Risk • Aug 01New major risk - Share price stabilityThe company's share price has been highly volatile over the past 3 months. It is more volatile than 90% of German stocks, typically moving 11% a week. This is considered a major risk. Share price volatility increases the risk of potential losses in the short-term as the stock tends to have larger drops in price more frequently than other stocks. It may also indicate the stock is highly sensitive to market conditions or economic conditions rather than being sensitive to its own business performance, which may also be inconsistent. Currently, the following risks have been identified for the company: Major Risks Share price has been highly volatile over the past 3 months (11% average weekly change). High level of non-cash earnings (23% accrual ratio).Valuation Update With 7 Day Price Move • Jul 30Investor sentiment improves as stock rises 16%After last week's 16% share price gain to €6.80, the stock trades at a forward P/E ratio of 11x. Average forward P/E is 17x in the Pharmaceuticals industry in Germany. Total returns to shareholders of 588% over the past three years. Simply Wall St's valuation model estimates the intrinsic value at €13.03 per share.Reported Earnings • May 10First quarter 2024 earnings released: EPS: US$0.21 (vs US$0.10 in 1Q 2023)First quarter 2024 results: EPS: US$0.21 (up from US$0.10 in 1Q 2023). Revenue: US$5.87m (up 20% from 1Q 2023). Net income: US$4.92m (up 88% from 1Q 2023). Profit margin: 84% (up from 54% in 1Q 2023). The increase in margin was primarily driven by lower expenses. Revenue is forecast to grow 1.8% p.a. on average during the next 3 years, compared to a 3.4% growth forecast for the Pharmaceuticals industry in Germany. Over the last 3 years on average, earnings per share has increased by 60% per year but the company’s share price has increased by 89% per year, which means it is tracking significantly ahead of earnings growth.お知らせ • Apr 09Cipher Pharmaceuticals Inc., Annual General Meeting, Jun 14, 2024Cipher Pharmaceuticals Inc., Annual General Meeting, Jun 14, 2024.Valuation Update With 7 Day Price Move • Mar 21Investor sentiment improves as stock rises 25%After last week's 25% share price gain to €5.95, the stock trades at a forward P/E ratio of 18x. Average forward P/E is 15x in the Pharmaceuticals industry in Germany. Total returns to shareholders of 717% over the past three years.Reported Earnings • Mar 15Full year 2023 earnings released: EPS: US$0.81 (vs US$1.05 in FY 2022)Full year 2023 results: EPS: US$0.81 (down from US$1.05 in FY 2022). Revenue: US$21.2m (up 2.4% from FY 2022). Net income: US$20.4m (down 24% from FY 2022). Profit margin: 96% (down from 129% in FY 2022). Revenue is forecast to grow 2.2% p.a. on average during the next 3 years, compared to a 3.3% growth forecast for the Pharmaceuticals industry in Germany. Over the last 3 years on average, earnings per share has increased by 69% per year but the company’s share price has increased by 99% per year, which means it is tracking significantly ahead of earnings growth.お知らせ • Mar 09Cipher Pharmaceuticals Inc. to Report Q4, 2023 Results on Mar 14, 2024Cipher Pharmaceuticals Inc. announced that they will report Q4, 2023 results After-Market on Mar 14, 2024Valuation Update With 7 Day Price Move • Feb 17Investor sentiment improves as stock rises 20%After last week's 20% share price gain to €5.30, the stock trades at a forward P/E ratio of 14x. Average forward P/E is 16x in the Pharmaceuticals industry in Germany. Total returns to shareholders of 772% over the past three years.Valuation Update With 7 Day Price Move • Jan 06Investor sentiment improves as stock rises 16%After last week's 16% share price gain to €4.30, the stock trades at a forward P/E ratio of 13x. Average forward P/E is 17x in the Pharmaceuticals industry in Europe. Total returns to shareholders of 481% over the past three years.Valuation Update With 7 Day Price Move • Nov 16Investor sentiment improves as stock rises 24%After last week's 24% share price gain to €3.62, the stock trades at a forward P/E ratio of 11x. Average forward P/E is 18x in the Pharmaceuticals industry in Europe. Total returns to shareholders of 505% over the past three years.Reported Earnings • Nov 12Third quarter 2023 earnings released: EPS: US$0.28 (vs US$0.11 in 3Q 2022)Third quarter 2023 results: EPS: US$0.28 (up from US$0.11 in 3Q 2022). Revenue: US$6.07m (up 27% from 3Q 2022). Net income: US$7.03m (up 165% from 3Q 2022). Revenue is forecast to stay flat during the next 3 years compared to a 3.6% growth forecast for the Pharmaceuticals industry in Germany. Over the last 3 years on average, earnings per share has increased by 74% per year whereas the company’s share price has increased by 77% per year.お知らせ • Oct 28Cipher Pharmaceuticals Inc. to Report Q3, 2023 Results on Nov 09, 2023Cipher Pharmaceuticals Inc. announced that they will report Q3, 2023 results on Nov 09, 2023お知らせ • Sep 06Cipher Pharmaceuticals Inc. (TSX:CPH) announces an Equity Buyback for CAD 6 million worth of its shares.Cipher Pharmaceuticals Inc. (TSX:CPH) announces a share repurchase program. Under the substantial issuer bid, the company will repurchase up to CAD 6 million worth of its outstanding shares. The shares will be tendered at a price of not less than CAD 3.95 per share and not more than CAD 4.75 per share. The company plans to fund the offer from available cash on hand. The shares purchased under the offer will be cancelled. If the aggregate cost to purchase the tendered shares exceeds $6 million, the company will accept such shares on a pro-rata basis after giving effect to “odd lot” tenders, which will not be subject to pro-ration. The bid will expire on October 11, 2023, unless extended or withdrawn.Reported Earnings • Aug 11Second quarter 2023 earnings released: EPS: US$0.12 (vs US$0.085 in 2Q 2022)Second quarter 2023 results: EPS: US$0.12 (up from US$0.085 in 2Q 2022). Revenue: US$5.29m (down 4.9% from 2Q 2022). Net income: US$3.07m (up 43% from 2Q 2022). Profit margin: 58% (up from 39% in 2Q 2022). The increase in margin was driven by lower expenses. Revenue is forecast to stay flat during the next 3 years compared to a 3.1% growth forecast for the Pharmaceuticals industry in Germany. Over the last 3 years on average, earnings per share has increased by 75% per year but the company’s share price has only increased by 43% per year, which means it is significantly lagging earnings growth.お知らせ • Jul 29Cipher Pharmaceuticals Inc. to Report Q2, 2023 Results on Aug 10, 2023Cipher Pharmaceuticals Inc. announced that they will report Q2, 2023 results on Aug 10, 2023Board Change • Jun 02Less than half of directors are independentThere is 1 new director who has joined the board in the last 3 years. The new board member was an independent director. The company's board is composed of: 1 new director. 6 experienced directors. No highly experienced directors. 3 independent directors (4 non-independent directors). Independent Director Cathy Steiner was the last independent director to join the board, commencing their role in 2020. The following issues are considered to be risks according to the Simply Wall St Risk Model: Minority of independent directors. Insufficient board refreshment.Reported Earnings • May 13First quarter 2023 earnings released: EPS: US$0.10 (vs US$0.083 in 1Q 2022)First quarter 2023 results: EPS: US$0.10 (up from US$0.083 in 1Q 2022). Revenue: US$4.89m (down 9.8% from 1Q 2022). Net income: US$2.63m (up 22% from 1Q 2022). Profit margin: 54% (up from 40% in 1Q 2022). The increase in margin was driven by lower expenses. Revenue is forecast to stay flat during the next 3 years compared to a 3.8% growth forecast for the Pharmaceuticals industry in Germany. Over the last 3 years on average, earnings per share has increased by 71% per year but the company’s share price has only increased by 47% per year, which means it is significantly lagging earnings growth.お知らせ • May 05Cipher Pharmaceuticals Inc. to Report Q1, 2023 Results on May 11, 2023Cipher Pharmaceuticals Inc. announced that they will report Q1, 2023 results on May 11, 2023Reported Earnings • Mar 17Full year 2022 earnings released: EPS: US$1.05 (vs US$0.29 in FY 2021)Full year 2022 results: EPS: US$1.05 (up from US$0.29 in FY 2021). Revenue: US$20.7m (down 5.8% from FY 2021). Net income: US$26.6m (up 243% from FY 2021). Revenue is forecast to grow 2.9% p.a. on average during the next 2 years, compared to a 3.4% growth forecast for the Pharmaceuticals industry in Germany. Over the last 3 years on average, earnings per share has increased by 63% per year but the company’s share price has increased by 105% per year, which means it is tracking significantly ahead of earnings growth.お知らせ • Feb 14Cipher Pharmaceuticals Inc. Declares Quarterly Dividend, Payable on or About February 28, 2023On February 10, 2022, the Board of Directors of Cipher Pharmaceuticals Inc. declared a quarterly dividend of $0.0.01875 per share to shareholders of record on February 21, 2023, payable on or about February 28, 2023.Recent Insider Transactions • Dec 18Independent Director recently sold €56k worth of stockOn the 9th of December, Christian Godin sold around 21k shares on-market at roughly €2.65 per share. This transaction amounted to 18% of their direct individual holding at the time of the trade. This was the largest sale by an insider in the last 3 months. Insiders have been net sellers, collectively disposing of €32k more than they bought in the last 12 months.Reported Earnings • Nov 16Third quarter 2022 earnings released: EPS: US$0.11 (vs US$0.03 in 3Q 2021)Third quarter 2022 results: EPS: US$0.11 (up from US$0.03 in 3Q 2021). Revenue: US$4.79m (up 6.2% from 3Q 2021). Net income: US$2.65m (up 233% from 3Q 2021). Profit margin: 55% (up from 18% in 3Q 2021). The increase in margin was primarily driven by lower expenses. Revenue is forecast to stay flat during the next 3 years compared to a 3.9% growth forecast for the Pharmaceuticals industry in Germany. Over the last 3 years on average, earnings per share has increased by 48% per year whereas the company’s share price has increased by 45% per year.Reported Earnings • Nov 12Third quarter 2022 earnings released: EPS: US$0.11 (vs US$0.03 in 3Q 2021)Third quarter 2022 results: EPS: US$0.11 (up from US$0.03 in 3Q 2021). Revenue: US$4.79m (up 6.2% from 3Q 2021). Net income: US$2.65m (up 233% from 3Q 2021). Profit margin: 55% (up from 18% in 3Q 2021). The increase in margin was primarily driven by lower expenses. Revenue is forecast to stay flat during the next 3 years compared to a 4.1% growth forecast for the Pharmaceuticals industry in Germany. Over the last 3 years on average, earnings per share has increased by 48% per year whereas the company’s share price has increased by 46% per year.Reported Earnings • Aug 13Second quarter 2022 earnings released: EPS: US$0.08 (vs US$0.10 in 2Q 2021)Second quarter 2022 results: EPS: US$0.08 (down from US$0.10 in 2Q 2021). Revenue: US$5.56m (down 9.3% from 2Q 2021). Net income: US$2.15m (down 24% from 2Q 2021). Profit margin: 39% (down from 46% in 2Q 2021). The decrease in margin was primarily driven by lower revenue. Over the next year, revenue is forecast to grow 9.6%, compared to a 6.3% growth forecast for the industry in Germany. Over the last 3 years on average, earnings per share has increased by 47% per year but the company’s share price has only increased by 29% per year, which means it is significantly lagging earnings growth.Reported Earnings • May 14First quarter 2022 earnings released: EPS: US$0.08 (vs US$0.05 in 1Q 2021)First quarter 2022 results: EPS: US$0.08 (up from US$0.05 in 1Q 2021). Revenue: US$5.42m (flat on 1Q 2021). Net income: US$2.15m (up 61% from 1Q 2021). Profit margin: 40% (up from 25% in 1Q 2021). Over the next year, revenue is forecast to grow 7.0%, compared to a 7.1% growth forecast for the industry in Germany. Over the last 3 years on average, earnings per share has increased by 45% per year but the company’s share price has only increased by 24% per year, which means it is significantly lagging earnings growth.Valuation Update With 7 Day Price Move • Mar 24Investor sentiment improved over the past weekAfter last week's 15% share price gain to €1.64, the stock trades at a forward P/E ratio of 5x. Average forward P/E is 20x in the Pharmaceuticals industry in Europe. Total returns to shareholders of 70% over the past three years.Reported Earnings • Mar 19Full year 2021 earnings: Revenues and EPS in line with analyst expectationsFull year 2021 results: EPS: US$0.29 (up from US$0.16 in FY 2020). Revenue: US$21.9m (up 1.6% from FY 2020). Net income: US$7.76m (up 77% from FY 2020). Profit margin: 35% (up from 20% in FY 2020). The increase in margin was primarily driven by lower expenses. Revenue was in line with analyst estimates. Over the next year, revenue is forecast to grow 8.5%, compared to a 8.2% growth forecast for the pharmaceuticals industry in Germany. Over the last 3 years on average, earnings per share has increased by 45% per year but the company’s share price has only increased by 16% per year, which means it is significantly lagging earnings growth.Valuation Update With 7 Day Price Move • Feb 09Investor sentiment improved over the past weekAfter last week's 19% share price gain to €1.45, the stock trades at a forward P/E ratio of 5x. Average forward P/E is 19x in the Pharmaceuticals industry in Europe. Total returns to shareholders of 19% over the past three years.Valuation Update With 7 Day Price Move • Dec 25Investor sentiment improved over the past weekAfter last week's 16% share price gain to €1.28, the stock trades at a forward P/E ratio of 4x. Average forward P/E is 21x in the Pharmaceuticals industry in Europe. Total returns to shareholders of 25% over the past three years.Reported Earnings • Nov 12Third quarter 2021 earnings released: EPS US$0.03 (vs US$0.059 in 3Q 2020)The company reported a poor third quarter result with weaker earnings, revenues and profit margins. Third quarter 2021 results: Revenue: US$4.51m (down 6.9% from 3Q 2020). Net income: US$796.0k (down 50% from 3Q 2020). Profit margin: 18% (down from 33% in 3Q 2020). Over the last 3 years on average, earnings per share has increased by 24% per year but the company’s share price has only increased by 12% per year, which means it is significantly lagging earnings growth.Valuation Update With 7 Day Price Move • Sep 14Investor sentiment improved over the past weekAfter last week's 17% share price gain to €1.60, the stock trades at a forward P/E ratio of 6x. Average forward P/E is 24x in the Pharmaceuticals industry in Europe. Total loss to shareholders of 23% over the past three years.Valuation Update With 7 Day Price Move • Aug 19Investor sentiment improved over the past weekAfter last week's 19% share price gain to US$1.34, the stock trades at a forward P/E ratio of 4x. Average forward P/E is 25x in the Pharmaceuticals industry in Europe. Total loss to shareholders of 35% over the past three years.Reported Earnings • Aug 14Second quarter 2021 earnings released: EPS US$0.11 (vs US$0.015 in 2Q 2020)The company reported a strong second quarter result with improved earnings, revenues and profit margins. Second quarter 2021 results: Revenue: US$6.13m (up 30% from 2Q 2020). Net income: US$2.82m (up US$2.41m from 2Q 2020). Profit margin: 46% (up from 8.7% in 2Q 2020). Over the last 3 years on average, earnings per share has remained flat but the company’s share price has fallen by 16% per year, which means it is significantly lagging earnings.Valuation Update With 7 Day Price Move • Jun 08Investor sentiment improved over the past weekAfter last week's 20% share price gain to US$1.06, the stock trades at a forward P/E ratio of 5x. Average forward P/E is 24x in the Pharmaceuticals industry in Europe. Total loss to shareholders of 38% over the past three years.Reported Earnings • May 16First quarter 2021 earnings released: EPS US$0.05 (vs US$0.092 in 1Q 2020)The company reported a poor first quarter result with weaker earnings, revenues and profit margins. First quarter 2021 results: Revenue: US$5.45m (down 7.7% from 1Q 2020). Net income: US$1.34m (down 46% from 1Q 2020). Profit margin: 25% (down from 42% in 1Q 2020). Over the last 3 years on average, earnings per share has fallen by 27% per year and the company’s share price has also fallen by 27% per year.Is New 90 Day High Low • Jan 08New 90-day high: €0.74The company is up 9.0% from its price of €0.68 on 09 October 2020. The German market is up 8.0% over the last 90 days, indicating the company outperformed over that time. However, it underperformed the Pharmaceuticals industry, which is up 11% over the same period. According to the Simply Wall St valuation model, the estimated intrinsic value of the company is €1.71 per share.Reported Earnings • Nov 14Third quarter 2020 earnings released: EPS US$0.06The company reported a decent third quarter result with improved earnings and profit margins, although revenues were weaker. Third quarter 2020 results: Revenue: US$4.85m (down 16% from 3Q 2019). Net income: US$1.60m (up US$3.79m from 3Q 2019). Profit margin: 33% (up from net loss in 3Q 2019). The move to profitability was driven by lower expenses. Over the last 3 years on average, earnings per share has fallen by 45% per year whereas the company’s share price has fallen by 40% per year.Analyst Estimate Surprise Post Earnings • Nov 14Revenue beats expectationsRevenue exceeded analyst estimates by 23%. Over the next year, revenue is expected to shrink by 24% compared to a 2.8% growth forecast for the Pharmaceuticals industry in Germany.Is New 90 Day High Low • Nov 10New 90-day low: €0.59The company is down 32% from its price of €0.87 on 12 August 2020. The German market is flat over the last 90 days, indicating the company underperformed over that time. It also underperformed the Pharmaceuticals industry, which is down 2.0% over the same period.Is New 90 Day High Low • Oct 21New 90-day low: €0.64The company is down 31% from its price of €0.92 on 23 July 2020. The German market is down 2.0% over the last 90 days, indicating the company underperformed over that time. It also underperformed the Pharmaceuticals industry, which is down 10.0% over the same period. According to the Simply Wall St valuation model, the estimated intrinsic value of the company is €2.55 per share.お知らせ • Oct 10Cipher Pharmaceuticals Inc. Approves the Appointment of Cathy Steiner as DirectorCipher Pharmaceuticals Inc. announced the voting results for the election of directors at its Annual Meeting of Shareholders held earlier October 8, 2020. The shareholders approved the appointment of Cathy Steiner as director.Is New 90 Day High Low • Sep 28New 90-day low: €0.69The company is down 10.0% from its price of €0.77 on 30 June 2020. The German market is up 1.0% over the last 90 days, indicating the company underperformed over that time. It also underperformed the Pharmaceuticals industry, which is down 4.0% over the same period. According to the Simply Wall St valuation model, the estimated intrinsic value of the company is €2.58 per share.収支内訳Cipher Pharmaceuticals の稼ぎ方とお金の使い方。LTMベースの直近の報告された収益に基づく。収益と収入の歴史DB:PHE 収益、費用、利益 ( )USD Millions日付収益収益G+A経費研究開発費31 Mar 26513114031 Dec 25502716030 Sep 25501717030 Jun 25481218031 Mar 2540916031 Dec 24331212030 Sep 2426169030 Jun 2422236031 Mar 2422236031 Dec 2321205030 Sep 2321325030 Jun 2320285031 Mar 2320275031 Dec 2221275030 Sep 2222105030 Jun 222185031 Mar 222295031 Dec 212285030 Sep 212256030 Jun 212366031 Mar 212136031 Dec 202246030 Sep 202176030 Jun 202235031 Mar 202346031 Dec 192238030 Sep 1923-111030 Jun 1922213031 Mar 1923314131 Dec 1823114130 Sep 1828613130 Jun 1834913031 Mar 18371113031 Dec 17401113030 Sep 1734713030 Jun 1732513031 Mar 1731114131 Dec 1630416130 Sep 1633623130 Jun 1634228031 Mar 1634129031 Dec 1534229130 Sep 15323211質の高い収益: PHEは 高品質の収益 を持っています。利益率の向上: PHEの現在の純利益率 (60.6%)は、昨年(23.4%)よりも高くなっています。フリー・キャッシュフローと収益の比較過去の収益成長分析収益動向: PHEの収益は過去 5 年間で年間19.2%増加しました。成長の加速: PHEの過去 1 年間の収益成長率 ( 233.9% ) は、5 年間の平均 ( 年間19.2%を上回っています。収益対業界: PHEの過去 1 年間の収益成長率 ( 233.9% ) はPharmaceuticals業界15.6%を上回りました。株主資本利益率高いROE: PHEの 自己資本利益率 ( 23.3% ) は 高い とみなされます。総資産利益率使用総資本利益率過去の好業績企業の発掘7D1Y7D1Y7D1YPharmaceuticals-biotech 、過去の業績が好調な企業。View Financial Health企業分析と財務データの現状データ最終更新日（UTC時間）企業分析2026/07/12 05:57終値2026/07/10 00:00収益2026/03/31年間収益2025/12/31データソース企業分析に使用したデータはS&P Global Market Intelligence LLC のものです。本レポートを作成するための分析モデルでは、以下のデータを使用しています。データは正規化されているため、ソースが利用可能になるまでに時間がかかる場合があります。パッケージデータタイムフレーム米国ソース例会社財務10年損益計算書キャッシュ・フロー計算書貸借対照表SECフォーム10-KSECフォーム10-Qアナリストのコンセンサス予想+プラス3年予想財務アナリストの目標株価アナリストリサーチレポートBlue Matrix市場価格30年株価配当、分割、措置ICEマーケットデータSECフォームS-1所有権10年トップ株主インサイダー取引SECフォーム4SECフォーム13Dマネジメント10年リーダーシップ・チーム取締役会SECフォーム10-KSECフォームDEF 14A主な進展10年会社からのお知らせSECフォーム8-K* 米国証券を対象とした例であり、非米国証券については、同等の規制書式および情報源を使用。特に断りのない限り、すべての財務データは1年ごとの期間に基づいていますが、四半期ごとに更新されます。これは、TTM（Trailing Twelve Month）またはLTM（Last Twelve Month）データとして知られています。詳細はこちら。分析モデルとスノーフレークこのレポートを生成するために使用した分析モデルの詳細は、当社の Github ページ でご覧いただけます。また、レポートの使い方に関する ガイド や YouTube の チュートリアル もご用意しています。シンプリー・ウォールストリート分析モデルを設計・構築した世界トップクラスのチームについてご紹介します。業界およびセクターの指標私たちの業界とセクションの指標は、Simply Wall Stによって6時間ごとに計算されます。アナリスト筋Cipher Pharmaceuticals Inc. 4 これらのアナリストのうち、弊社レポートのインプットとして使用した売上高または利益の予想を提出したのは、 。アナリストの投稿は一日中更新されます。8 アナリスト機関David NovakATB Cormark Historical (Cormark Securities)Tania Armstrong-WhitworthCanaccord GenuityPrakash GowdCIBC Capital Markets5 その他のアナリストを表示
お知らせ • Apr 30Cipher Pharmaceuticals Inc. to Report Q1, 2026 Results on May 07, 2026Cipher Pharmaceuticals Inc. announced that they will report Q1, 2026 results After-Market on May 07, 2026
お知らせ • Mar 05Cipher Pharmaceuticals Inc. to Report Q4, 2025 Results on Mar 12, 2026Cipher Pharmaceuticals Inc. announced that they will report Q4, 2025 results at 4:00 PM, US Eastern Standard Time on Mar 12, 2026
お知らせ • Oct 30Cipher Pharmaceuticals Inc. to Report Q3, 2025 Results on Nov 06, 2025Cipher Pharmaceuticals Inc. announced that they will report Q3, 2025 results After-Market on Nov 06, 2025
お知らせ • Jul 29Cipher Pharmaceuticals Inc. to Report Q2, 2025 Results on Aug 07, 2025Cipher Pharmaceuticals Inc. announced that they will report Q2, 2025 results at 4:00 PM, US Eastern Standard Time on Aug 07, 2025
お知らせ • May 03Cipher Pharmaceuticals Inc. to Report Q1, 2025 Results on May 08, 2025Cipher Pharmaceuticals Inc. announced that they will report Q1, 2025 results After-Market on May 08, 2025
お知らせ • Mar 12Cipher Pharmaceuticals Inc. to Report Q4, 2024 Results on Mar 18, 2025Cipher Pharmaceuticals Inc. announced that they will report Q4, 2024 results at 4:00 PM, US Eastern Standard Time on Mar 18, 2025
Board Change • Jul 01Insufficient new directorsNo new directors have joined the board in the last 3 years. The company's board is composed of: No new directors. 3 experienced directors. No highly experienced directors. Independent Director Doug Deeth was the last director to join the board, commencing their role in 2023. The company’s insufficient board refreshment is considered a risk according to the Simply Wall St Risk Model.
お知らせ • Apr 30Cipher Pharmaceuticals Inc. to Report Q1, 2026 Results on May 07, 2026Cipher Pharmaceuticals Inc. announced that they will report Q1, 2026 results After-Market on May 07, 2026
お知らせ • Apr 21Cipher Pharmaceuticals Inc., Annual General Meeting, Jun 18, 2026Cipher Pharmaceuticals Inc., Annual General Meeting, Jun 18, 2026. Location: ontario, toronto Canada
お知らせ • Mar 05Cipher Pharmaceuticals Inc. to Report Q4, 2025 Results on Mar 12, 2026Cipher Pharmaceuticals Inc. announced that they will report Q4, 2025 results at 4:00 PM, US Eastern Standard Time on Mar 12, 2026
お知らせ • Jan 29Cipher Pharmaceuticals Announces Health Canada's Acceptance for Review of New Drug Submission for Natroba™? (Spinosad)Cipher Pharmaceuticals Inc. announced that Health Canada has accepted for review Cipher's new drug submission ("NDS") for Natroba™? (Spinosad), for the treatment of head lice and scabies. Natroba™? (Spinosad) is widely recognized as one of the most effective treatments for the two parasitic indications of head lice and sc babies in the U.S. It is superior to the widely used permethrin 1% for treating head lice and is the only treatment in the U.S. that meets the FDA's criteria for a " complete cure" (elimination of all signs and symptoms) in eradicating sc babies infestations with a single application. Cipher acquired Natroba™? (spinosad) in July 2024, and since acquisition has marketed and distributed the product in the United States ("U.S.) market, through its commercial infrastructure.
お知らせ • Oct 30Cipher Pharmaceuticals Inc. to Report Q3, 2025 Results on Nov 06, 2025Cipher Pharmaceuticals Inc. announced that they will report Q3, 2025 results After-Market on Nov 06, 2025
お知らせ • Aug 28Cipher Pharmaceuticals Inc. Announces the Passing of Board Director and Chairman of Audit Committee Harold M. WolkinCipher Pharmaceuticals Inc. announced the passing of Harold M. Wolkin, a valued member of the Company's Board of Directors and Chairman of the Audit Committee. Mr. Wolkin was a very active member of the Board and his deep understanding of the capital markets and unwavering commitment to the Company's growth and governance were tremendously valuable to the Company. During his tenure, he played a vital role in guiding strategic initiatives, supporting management, and representing the Company and its shareholders with integrity. Harold was a very well-known and highly respective member of the Canadian capital markets community and he will truly be missed by those that knew him.
お知らせ • Jul 29Cipher Pharmaceuticals Inc. to Report Q2, 2025 Results on Aug 07, 2025Cipher Pharmaceuticals Inc. announced that they will report Q2, 2025 results at 4:00 PM, US Eastern Standard Time on Aug 07, 2025
お知らせ • May 03Cipher Pharmaceuticals Inc. to Report Q1, 2025 Results on May 08, 2025Cipher Pharmaceuticals Inc. announced that they will report Q1, 2025 results After-Market on May 08, 2025
お知らせ • Apr 09Cipher Pharmaceuticals Inc., Annual General Meeting, Jun 13, 2025Cipher Pharmaceuticals Inc., Annual General Meeting, Jun 13, 2025. Location: ontario, toronto Canada
お知らせ • Mar 12Cipher Pharmaceuticals Inc. to Report Q4, 2024 Results on Mar 18, 2025Cipher Pharmaceuticals Inc. announced that they will report Q4, 2024 results at 4:00 PM, US Eastern Standard Time on Mar 18, 2025
Valuation Update With 7 Day Price Move • Nov 14Investor sentiment deteriorates as stock falls 17%After last week's 17% share price decline to €8.55, the stock trades at a forward P/E ratio of 12x. Average forward P/E is 14x in the Pharmaceuticals industry in Germany. Total returns to shareholders of 466% over the past three years.
Reported Earnings • Nov 10Third quarter 2024 earnings released: EPS: US$0.011 (vs US$0.28 in 3Q 2023)Third quarter 2024 results: EPS: US$0.011 (down from US$0.28 in 3Q 2023). Revenue: US$10.4m (up 71% from 3Q 2023). Net income: US$283.0k (down 96% from 3Q 2023). Profit margin: 2.7% (down from 116% in 3Q 2023). Revenue is forecast to grow 19% p.a. on average during the next 3 years, compared to a 3.4% growth forecast for the Pharmaceuticals industry in Germany. Over the last 3 years on average, earnings per share has increased by 36% per year but the company’s share price has increased by 89% per year, which means it is tracking significantly ahead of earnings growth.
New Risk • Nov 10New major risk - Earnings qualityThe company has a high level of non-cash earnings. Accrual ratio: 101% This is considered a major risk. Non-cash earnings can arise from many different things. However, if a company consistently has a high level of non-cash earnings, it may be a sign that they are recognizing revenue from customers before the full value of the sales are received as cash or they are not depreciating the value of their assets appropriately. These are practices that inflate earnings, while not providing a similar increase to cash flows. Companies in some select industries naturally have a high level of non-cash earnings and it is not a major concern. However, in the worst case scenario it can be an early sign of performance manipulation by management. Currently, the following risks have been identified for the company: Major Risk High level of non-cash earnings (101% accrual ratio). Minor Risks Share price has been volatile over the past 3 months (9.8% average weekly change). Profit margins are more than 30% lower than last year (60% net profit margin). Shareholders have been diluted in the past year (6.5% increase in shares outstanding).
お知らせ • Nov 04Cipher Pharmaceuticals Inc. to Report Q3, 2024 Results on Nov 07, 2024Cipher Pharmaceuticals Inc. announced that they will report Q3, 2024 results After-Market on Nov 07, 2024
お知らせ • Oct 08Cipher Pharmaceuticals Inc. Appoints Hamed Ghanei as Chief Business OfficerCipher Pharmaceuticals Inc. announced the appointment of Hamed Ghanei as Chief Business Officer. Dr. Ghanei has over 15 years of experience in specialty pharmaceuticals, venture funds, and healthcare investment banking. Throughout his career, he has led the evaluation of over 500 licensing and M&A opportunities and has been involved in five commercial product launches. He has successfully negotiated over 20 transactions with total value exceeding $1 billion. Dr. Ghanei holds a B.Sc. from the University of Waterloo, a M.Sc. in Microbiology and Biochemistry from the University of Guelph, and a Ph.D. in Medical Biophysics from the University of Toronto.
Valuation Update With 7 Day Price Move • Oct 04Investor sentiment improves as stock rises 15%After last week's 15% share price gain to €10.20, the stock trades at a forward P/E ratio of 14x. Average forward P/E is 14x in the Pharmaceuticals industry in Germany. Total returns to shareholders of 534% over the past three years.
Valuation Update With 7 Day Price Move • Sep 13Investor sentiment deteriorates as stock falls 21%After last week's 21% share price decline to €9.35, the stock trades at a forward P/E ratio of 14x. Average forward P/E is 15x in the Pharmaceuticals industry in Germany. Total returns to shareholders of 483% over the past three years.
Valuation Update With 7 Day Price Move • Aug 20Investor sentiment improves as stock rises 18%After last week's 18% share price gain to €10.40, the stock trades at a forward P/E ratio of 14x. Average forward P/E is 17x in the Pharmaceuticals industry in Germany. Total returns to shareholders of 584% over the past three years.
お知らせ • Aug 09+ 1 more updateCipher Pharmaceuticals Inc. Announces CFO ChangesEffective August 10, 2024, and as a result of the Natroba Acquisition, Cipher Pharmaceuticals Inc.'s Chief Financial Officer, Bryan Jacobs, will assume the title of President of the Company. His mandate will be to manage the transition and integration of the U.S. operations and commercial sales team. The Company's Vice President, Finance, Ryan Mailling, has in turn been appointed as the Chief Financial Officer of the Company, taking over from Mr. Jacobs.
Reported Earnings • Aug 09Second quarter 2024 earnings released: EPS: US$0.12 (vs US$0.12 in 2Q 2023)Second quarter 2024 results: EPS: US$0.12 (down from US$0.12 in 2Q 2023). Revenue: US$5.30m (flat on 2Q 2023). Net income: US$3.00m (down 2.5% from 2Q 2023). Profit margin: 56% (down from 58% in 2Q 2023). Revenue is forecast to grow 20% p.a. on average during the next 3 years, compared to a 3.8% growth forecast for the Pharmaceuticals industry in Germany. Over the last 3 years on average, earnings per share has increased by 49% per year but the company’s share price has increased by 102% per year, which means it is tracking significantly ahead of earnings growth.
お知らせ • Aug 02Cipher Pharmaceuticals Inc. to Report Q2, 2024 Results on Aug 08, 2024Cipher Pharmaceuticals Inc. announced that they will report Q2, 2024 results After-Market on Aug 08, 2024
New Risk • Aug 01New major risk - Share price stabilityThe company's share price has been highly volatile over the past 3 months. It is more volatile than 90% of German stocks, typically moving 11% a week. This is considered a major risk. Share price volatility increases the risk of potential losses in the short-term as the stock tends to have larger drops in price more frequently than other stocks. It may also indicate the stock is highly sensitive to market conditions or economic conditions rather than being sensitive to its own business performance, which may also be inconsistent. Currently, the following risks have been identified for the company: Major Risks Share price has been highly volatile over the past 3 months (11% average weekly change). High level of non-cash earnings (23% accrual ratio).
Valuation Update With 7 Day Price Move • Jul 30Investor sentiment improves as stock rises 16%After last week's 16% share price gain to €6.80, the stock trades at a forward P/E ratio of 11x. Average forward P/E is 17x in the Pharmaceuticals industry in Germany. Total returns to shareholders of 588% over the past three years. Simply Wall St's valuation model estimates the intrinsic value at €13.03 per share.
Reported Earnings • May 10First quarter 2024 earnings released: EPS: US$0.21 (vs US$0.10 in 1Q 2023)First quarter 2024 results: EPS: US$0.21 (up from US$0.10 in 1Q 2023). Revenue: US$5.87m (up 20% from 1Q 2023). Net income: US$4.92m (up 88% from 1Q 2023). Profit margin: 84% (up from 54% in 1Q 2023). The increase in margin was primarily driven by lower expenses. Revenue is forecast to grow 1.8% p.a. on average during the next 3 years, compared to a 3.4% growth forecast for the Pharmaceuticals industry in Germany. Over the last 3 years on average, earnings per share has increased by 60% per year but the company’s share price has increased by 89% per year, which means it is tracking significantly ahead of earnings growth.
お知らせ • Apr 09Cipher Pharmaceuticals Inc., Annual General Meeting, Jun 14, 2024Cipher Pharmaceuticals Inc., Annual General Meeting, Jun 14, 2024.
Valuation Update With 7 Day Price Move • Mar 21Investor sentiment improves as stock rises 25%After last week's 25% share price gain to €5.95, the stock trades at a forward P/E ratio of 18x. Average forward P/E is 15x in the Pharmaceuticals industry in Germany. Total returns to shareholders of 717% over the past three years.
Reported Earnings • Mar 15Full year 2023 earnings released: EPS: US$0.81 (vs US$1.05 in FY 2022)Full year 2023 results: EPS: US$0.81 (down from US$1.05 in FY 2022). Revenue: US$21.2m (up 2.4% from FY 2022). Net income: US$20.4m (down 24% from FY 2022). Profit margin: 96% (down from 129% in FY 2022). Revenue is forecast to grow 2.2% p.a. on average during the next 3 years, compared to a 3.3% growth forecast for the Pharmaceuticals industry in Germany. Over the last 3 years on average, earnings per share has increased by 69% per year but the company’s share price has increased by 99% per year, which means it is tracking significantly ahead of earnings growth.
お知らせ • Mar 09Cipher Pharmaceuticals Inc. to Report Q4, 2023 Results on Mar 14, 2024Cipher Pharmaceuticals Inc. announced that they will report Q4, 2023 results After-Market on Mar 14, 2024
Valuation Update With 7 Day Price Move • Feb 17Investor sentiment improves as stock rises 20%After last week's 20% share price gain to €5.30, the stock trades at a forward P/E ratio of 14x. Average forward P/E is 16x in the Pharmaceuticals industry in Germany. Total returns to shareholders of 772% over the past three years.
Valuation Update With 7 Day Price Move • Jan 06Investor sentiment improves as stock rises 16%After last week's 16% share price gain to €4.30, the stock trades at a forward P/E ratio of 13x. Average forward P/E is 17x in the Pharmaceuticals industry in Europe. Total returns to shareholders of 481% over the past three years.
Valuation Update With 7 Day Price Move • Nov 16Investor sentiment improves as stock rises 24%After last week's 24% share price gain to €3.62, the stock trades at a forward P/E ratio of 11x. Average forward P/E is 18x in the Pharmaceuticals industry in Europe. Total returns to shareholders of 505% over the past three years.
Reported Earnings • Nov 12Third quarter 2023 earnings released: EPS: US$0.28 (vs US$0.11 in 3Q 2022)Third quarter 2023 results: EPS: US$0.28 (up from US$0.11 in 3Q 2022). Revenue: US$6.07m (up 27% from 3Q 2022). Net income: US$7.03m (up 165% from 3Q 2022). Revenue is forecast to stay flat during the next 3 years compared to a 3.6% growth forecast for the Pharmaceuticals industry in Germany. Over the last 3 years on average, earnings per share has increased by 74% per year whereas the company’s share price has increased by 77% per year.
お知らせ • Oct 28Cipher Pharmaceuticals Inc. to Report Q3, 2023 Results on Nov 09, 2023Cipher Pharmaceuticals Inc. announced that they will report Q3, 2023 results on Nov 09, 2023
お知らせ • Sep 06Cipher Pharmaceuticals Inc. (TSX:CPH) announces an Equity Buyback for CAD 6 million worth of its shares.Cipher Pharmaceuticals Inc. (TSX:CPH) announces a share repurchase program. Under the substantial issuer bid, the company will repurchase up to CAD 6 million worth of its outstanding shares. The shares will be tendered at a price of not less than CAD 3.95 per share and not more than CAD 4.75 per share. The company plans to fund the offer from available cash on hand. The shares purchased under the offer will be cancelled. If the aggregate cost to purchase the tendered shares exceeds $6 million, the company will accept such shares on a pro-rata basis after giving effect to “odd lot” tenders, which will not be subject to pro-ration. The bid will expire on October 11, 2023, unless extended or withdrawn.
Reported Earnings • Aug 11Second quarter 2023 earnings released: EPS: US$0.12 (vs US$0.085 in 2Q 2022)Second quarter 2023 results: EPS: US$0.12 (up from US$0.085 in 2Q 2022). Revenue: US$5.29m (down 4.9% from 2Q 2022). Net income: US$3.07m (up 43% from 2Q 2022). Profit margin: 58% (up from 39% in 2Q 2022). The increase in margin was driven by lower expenses. Revenue is forecast to stay flat during the next 3 years compared to a 3.1% growth forecast for the Pharmaceuticals industry in Germany. Over the last 3 years on average, earnings per share has increased by 75% per year but the company’s share price has only increased by 43% per year, which means it is significantly lagging earnings growth.
お知らせ • Jul 29Cipher Pharmaceuticals Inc. to Report Q2, 2023 Results on Aug 10, 2023Cipher Pharmaceuticals Inc. announced that they will report Q2, 2023 results on Aug 10, 2023
Board Change • Jun 02Less than half of directors are independentThere is 1 new director who has joined the board in the last 3 years. The new board member was an independent director. The company's board is composed of: 1 new director. 6 experienced directors. No highly experienced directors. 3 independent directors (4 non-independent directors). Independent Director Cathy Steiner was the last independent director to join the board, commencing their role in 2020. The following issues are considered to be risks according to the Simply Wall St Risk Model: Minority of independent directors. Insufficient board refreshment.
Reported Earnings • May 13First quarter 2023 earnings released: EPS: US$0.10 (vs US$0.083 in 1Q 2022)First quarter 2023 results: EPS: US$0.10 (up from US$0.083 in 1Q 2022). Revenue: US$4.89m (down 9.8% from 1Q 2022). Net income: US$2.63m (up 22% from 1Q 2022). Profit margin: 54% (up from 40% in 1Q 2022). The increase in margin was driven by lower expenses. Revenue is forecast to stay flat during the next 3 years compared to a 3.8% growth forecast for the Pharmaceuticals industry in Germany. Over the last 3 years on average, earnings per share has increased by 71% per year but the company’s share price has only increased by 47% per year, which means it is significantly lagging earnings growth.
お知らせ • May 05Cipher Pharmaceuticals Inc. to Report Q1, 2023 Results on May 11, 2023Cipher Pharmaceuticals Inc. announced that they will report Q1, 2023 results on May 11, 2023
Reported Earnings • Mar 17Full year 2022 earnings released: EPS: US$1.05 (vs US$0.29 in FY 2021)Full year 2022 results: EPS: US$1.05 (up from US$0.29 in FY 2021). Revenue: US$20.7m (down 5.8% from FY 2021). Net income: US$26.6m (up 243% from FY 2021). Revenue is forecast to grow 2.9% p.a. on average during the next 2 years, compared to a 3.4% growth forecast for the Pharmaceuticals industry in Germany. Over the last 3 years on average, earnings per share has increased by 63% per year but the company’s share price has increased by 105% per year, which means it is tracking significantly ahead of earnings growth.
お知らせ • Feb 14Cipher Pharmaceuticals Inc. Declares Quarterly Dividend, Payable on or About February 28, 2023On February 10, 2022, the Board of Directors of Cipher Pharmaceuticals Inc. declared a quarterly dividend of $0.0.01875 per share to shareholders of record on February 21, 2023, payable on or about February 28, 2023.
Recent Insider Transactions • Dec 18Independent Director recently sold €56k worth of stockOn the 9th of December, Christian Godin sold around 21k shares on-market at roughly €2.65 per share. This transaction amounted to 18% of their direct individual holding at the time of the trade. This was the largest sale by an insider in the last 3 months. Insiders have been net sellers, collectively disposing of €32k more than they bought in the last 12 months.
Reported Earnings • Nov 16Third quarter 2022 earnings released: EPS: US$0.11 (vs US$0.03 in 3Q 2021)Third quarter 2022 results: EPS: US$0.11 (up from US$0.03 in 3Q 2021). Revenue: US$4.79m (up 6.2% from 3Q 2021). Net income: US$2.65m (up 233% from 3Q 2021). Profit margin: 55% (up from 18% in 3Q 2021). The increase in margin was primarily driven by lower expenses. Revenue is forecast to stay flat during the next 3 years compared to a 3.9% growth forecast for the Pharmaceuticals industry in Germany. Over the last 3 years on average, earnings per share has increased by 48% per year whereas the company’s share price has increased by 45% per year.
Reported Earnings • Nov 12Third quarter 2022 earnings released: EPS: US$0.11 (vs US$0.03 in 3Q 2021)Third quarter 2022 results: EPS: US$0.11 (up from US$0.03 in 3Q 2021). Revenue: US$4.79m (up 6.2% from 3Q 2021). Net income: US$2.65m (up 233% from 3Q 2021). Profit margin: 55% (up from 18% in 3Q 2021). The increase in margin was primarily driven by lower expenses. Revenue is forecast to stay flat during the next 3 years compared to a 4.1% growth forecast for the Pharmaceuticals industry in Germany. Over the last 3 years on average, earnings per share has increased by 48% per year whereas the company’s share price has increased by 46% per year.
Reported Earnings • Aug 13Second quarter 2022 earnings released: EPS: US$0.08 (vs US$0.10 in 2Q 2021)Second quarter 2022 results: EPS: US$0.08 (down from US$0.10 in 2Q 2021). Revenue: US$5.56m (down 9.3% from 2Q 2021). Net income: US$2.15m (down 24% from 2Q 2021). Profit margin: 39% (down from 46% in 2Q 2021). The decrease in margin was primarily driven by lower revenue. Over the next year, revenue is forecast to grow 9.6%, compared to a 6.3% growth forecast for the industry in Germany. Over the last 3 years on average, earnings per share has increased by 47% per year but the company’s share price has only increased by 29% per year, which means it is significantly lagging earnings growth.
Reported Earnings • May 14First quarter 2022 earnings released: EPS: US$0.08 (vs US$0.05 in 1Q 2021)First quarter 2022 results: EPS: US$0.08 (up from US$0.05 in 1Q 2021). Revenue: US$5.42m (flat on 1Q 2021). Net income: US$2.15m (up 61% from 1Q 2021). Profit margin: 40% (up from 25% in 1Q 2021). Over the next year, revenue is forecast to grow 7.0%, compared to a 7.1% growth forecast for the industry in Germany. Over the last 3 years on average, earnings per share has increased by 45% per year but the company’s share price has only increased by 24% per year, which means it is significantly lagging earnings growth.
Valuation Update With 7 Day Price Move • Mar 24Investor sentiment improved over the past weekAfter last week's 15% share price gain to €1.64, the stock trades at a forward P/E ratio of 5x. Average forward P/E is 20x in the Pharmaceuticals industry in Europe. Total returns to shareholders of 70% over the past three years.
Reported Earnings • Mar 19Full year 2021 earnings: Revenues and EPS in line with analyst expectationsFull year 2021 results: EPS: US$0.29 (up from US$0.16 in FY 2020). Revenue: US$21.9m (up 1.6% from FY 2020). Net income: US$7.76m (up 77% from FY 2020). Profit margin: 35% (up from 20% in FY 2020). The increase in margin was primarily driven by lower expenses. Revenue was in line with analyst estimates. Over the next year, revenue is forecast to grow 8.5%, compared to a 8.2% growth forecast for the pharmaceuticals industry in Germany. Over the last 3 years on average, earnings per share has increased by 45% per year but the company’s share price has only increased by 16% per year, which means it is significantly lagging earnings growth.
Valuation Update With 7 Day Price Move • Feb 09Investor sentiment improved over the past weekAfter last week's 19% share price gain to €1.45, the stock trades at a forward P/E ratio of 5x. Average forward P/E is 19x in the Pharmaceuticals industry in Europe. Total returns to shareholders of 19% over the past three years.
Valuation Update With 7 Day Price Move • Dec 25Investor sentiment improved over the past weekAfter last week's 16% share price gain to €1.28, the stock trades at a forward P/E ratio of 4x. Average forward P/E is 21x in the Pharmaceuticals industry in Europe. Total returns to shareholders of 25% over the past three years.
Reported Earnings • Nov 12Third quarter 2021 earnings released: EPS US$0.03 (vs US$0.059 in 3Q 2020)The company reported a poor third quarter result with weaker earnings, revenues and profit margins. Third quarter 2021 results: Revenue: US$4.51m (down 6.9% from 3Q 2020). Net income: US$796.0k (down 50% from 3Q 2020). Profit margin: 18% (down from 33% in 3Q 2020). Over the last 3 years on average, earnings per share has increased by 24% per year but the company’s share price has only increased by 12% per year, which means it is significantly lagging earnings growth.
Valuation Update With 7 Day Price Move • Sep 14Investor sentiment improved over the past weekAfter last week's 17% share price gain to €1.60, the stock trades at a forward P/E ratio of 6x. Average forward P/E is 24x in the Pharmaceuticals industry in Europe. Total loss to shareholders of 23% over the past three years.
Valuation Update With 7 Day Price Move • Aug 19Investor sentiment improved over the past weekAfter last week's 19% share price gain to US$1.34, the stock trades at a forward P/E ratio of 4x. Average forward P/E is 25x in the Pharmaceuticals industry in Europe. Total loss to shareholders of 35% over the past three years.
Reported Earnings • Aug 14Second quarter 2021 earnings released: EPS US$0.11 (vs US$0.015 in 2Q 2020)The company reported a strong second quarter result with improved earnings, revenues and profit margins. Second quarter 2021 results: Revenue: US$6.13m (up 30% from 2Q 2020). Net income: US$2.82m (up US$2.41m from 2Q 2020). Profit margin: 46% (up from 8.7% in 2Q 2020). Over the last 3 years on average, earnings per share has remained flat but the company’s share price has fallen by 16% per year, which means it is significantly lagging earnings.
Valuation Update With 7 Day Price Move • Jun 08Investor sentiment improved over the past weekAfter last week's 20% share price gain to US$1.06, the stock trades at a forward P/E ratio of 5x. Average forward P/E is 24x in the Pharmaceuticals industry in Europe. Total loss to shareholders of 38% over the past three years.
Reported Earnings • May 16First quarter 2021 earnings released: EPS US$0.05 (vs US$0.092 in 1Q 2020)The company reported a poor first quarter result with weaker earnings, revenues and profit margins. First quarter 2021 results: Revenue: US$5.45m (down 7.7% from 1Q 2020). Net income: US$1.34m (down 46% from 1Q 2020). Profit margin: 25% (down from 42% in 1Q 2020). Over the last 3 years on average, earnings per share has fallen by 27% per year and the company’s share price has also fallen by 27% per year.
Is New 90 Day High Low • Jan 08New 90-day high: €0.74The company is up 9.0% from its price of €0.68 on 09 October 2020. The German market is up 8.0% over the last 90 days, indicating the company outperformed over that time. However, it underperformed the Pharmaceuticals industry, which is up 11% over the same period. According to the Simply Wall St valuation model, the estimated intrinsic value of the company is €1.71 per share.
Reported Earnings • Nov 14Third quarter 2020 earnings released: EPS US$0.06The company reported a decent third quarter result with improved earnings and profit margins, although revenues were weaker. Third quarter 2020 results: Revenue: US$4.85m (down 16% from 3Q 2019). Net income: US$1.60m (up US$3.79m from 3Q 2019). Profit margin: 33% (up from net loss in 3Q 2019). The move to profitability was driven by lower expenses. Over the last 3 years on average, earnings per share has fallen by 45% per year whereas the company’s share price has fallen by 40% per year.
Analyst Estimate Surprise Post Earnings • Nov 14Revenue beats expectationsRevenue exceeded analyst estimates by 23%. Over the next year, revenue is expected to shrink by 24% compared to a 2.8% growth forecast for the Pharmaceuticals industry in Germany.
Is New 90 Day High Low • Nov 10New 90-day low: €0.59The company is down 32% from its price of €0.87 on 12 August 2020. The German market is flat over the last 90 days, indicating the company underperformed over that time. It also underperformed the Pharmaceuticals industry, which is down 2.0% over the same period.
Is New 90 Day High Low • Oct 21New 90-day low: €0.64The company is down 31% from its price of €0.92 on 23 July 2020. The German market is down 2.0% over the last 90 days, indicating the company underperformed over that time. It also underperformed the Pharmaceuticals industry, which is down 10.0% over the same period. According to the Simply Wall St valuation model, the estimated intrinsic value of the company is €2.55 per share.
お知らせ • Oct 10Cipher Pharmaceuticals Inc. Approves the Appointment of Cathy Steiner as DirectorCipher Pharmaceuticals Inc. announced the voting results for the election of directors at its Annual Meeting of Shareholders held earlier October 8, 2020. The shareholders approved the appointment of Cathy Steiner as director.
Is New 90 Day High Low • Sep 28New 90-day low: €0.69The company is down 10.0% from its price of €0.77 on 30 June 2020. The German market is up 1.0% over the last 90 days, indicating the company underperformed over that time. It also underperformed the Pharmaceuticals industry, which is down 4.0% over the same period. According to the Simply Wall St valuation model, the estimated intrinsic value of the company is €2.58 per share.